History of tuberculosis as an independent prognostic factor for lung cancer survival

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 452-456

  Heuvers, Marlies E ^a   Aerts, Joachim G J V ^a   Hegmans, Joost P ^a   Veltman, Joris D ^a   Uitterlinden, André G ^a   Ruiter, Rikje ^a   Rodenburg, Eline M ^a   Hofman, Albert ^a   Bakker, Marleen ^a   Hoogsteden, Henk C ^a   Stricker, Bruno H ^a   van Klaveren, Rob J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Lung cancer; Prognostic factor; Survival; Tuberculosis

Indexed keywords

ACADEMIC ACHIEVEMENT; ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RISK FACTOR;

AGED; AGED, 80 AND OVER; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 84860513474     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.12.008     Document Type: Article

References (31)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907.
3. Wood R., Liang H., Wu H., Middelkoop K., Oni T., Rangaka M.X., et al. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis 2010, 14:406-412.
4. Shiels M.S., Albanes D., Virtamo J., Engels E.A. Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 2011, 20:672-678.
5. Chen Y.M., Chao J.Y., Tsai C.M., Lee P.Y., Perng R.P. Shortened survival of lung cancer patients initially presenting with pulmonary tuberculosis. Jpn J Clin Oncol 1996, 26:322-327.
6. Yu Y.H., Liao C.C., Hsu W.H., Chen H.J., Liao W.C., Muo C.H., et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol 2011, 6:32-37.
7. Engels E.A., Shen M., Chapman R.S., Pfeiffer R.M., Yu Y.Y., He X., et al. Tuberculosis and subsequent risk of lung cancer in Xuanwei, China. Int J Cancer 2009, 124:1183-1187.
8. Kawaguchi T., Takada M., Kubo A., Matsumura A., Fukai S., Tamura A., et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010, 5:620-630.
9. Hofman A., Breteler M.M., van Duijn C.M., Janssen H.L., Krestin G.P., Kuipers E.J., et al. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 2009, 24:553-572.
10. Fesinmeyer M.D., Goulart B., Blough D.K., Buchwald D., Ramsey S.D. Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites. Cancer 2010, 116:4810-4816.
11. Bramer G.R. International statistical classification of diseases and related health problems. Tenth revision. World Health Stat Q 1988, 41:32-36.
12. Funakoshi Y., Maeda H., Takeda S., Nojiri T., Kawamura T. Tumor histology affects the accuracy of clinical evaluative staging in primary lung cancer. Lung Cancer 2010, 70:195-199.
13. Kawaguchi T., Takada M., Kubo A., Matsumura A., Fukai S., Tamura A., et al. Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol 2010, 5:1011-1017.
14. de Jong W.K., Schaapveld M., Blaauwgeers J.L., Groen H.J. Pulmonary tumours in the Netherlands: focus on temporal trends in histology and stage and on rare tumours. Thorax 2008, 63:1096-1102.
15. Russell D.G. Who puts the tubercle in tuberculosis. Nat Rev Microbiol 2007, 5:39-47.
16. Saunders B.M., Britton W.J. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol 2007, 85:103-111.
17. Feng L., Xia Y., Garcia G.E., Hwang D., Wilson C.B. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest 1995, 95:1669-1675.
18. Fujiwara N., Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:281-286.
19. Nalbandian A., Yan B.S., Pichugin A., Bronson R.T., Kramnik I. Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene 2009, 28:1928-1938.
20. Ulrichs T., Kosmiadi G.A., Trusov V., Jorg S., Pradl L., Titukhina M., et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004, 204:217-228.
21. Ulrichs T., Kaufmann S.H. New insights into the function of granulomas in human tuberculosis. J Pathol 2006, 208:261-269.
22. Bergh J.C. Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes. Am Rev Respir Dis 1990, 142:S20-S26.
23. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
24. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
25. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med 2010, 10:369-373.
26. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183.
27. Kawasaki H., Nagai K., Yoshida J., Nishimura M., Nishiwaki Y. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 2002, 81:33-37.
28. Welsh T.J., Green R.H., Richardson D., Waller D.A., O'Byrne K.J., Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005, 23:8959-8967.
29. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263-274.
30. Koning C.C., Aarts M.J., Struikmans H., Poortmans P.M., Lybeert M.L., Jobsen J.J., et al. Mapping use of radiotherapy for patients with non-small cell lung cancer in the Netherlands between 1997 and 2008. Clin Oncol (R Coll Radiol) 2011.
31. Underwood J.M., Townsend J.S., Tai E., Davis S.P., Stewart S.L., White A., et al. Racial and regional disparities in lung cancer incidence. Cancer 2011.